Journal article
An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development
JH Salas, RA Urbanowicz, JD Guest, N Frumento, A Figueroa, KE Clark, Z Keck, VM Cowton, SJ Cole, AH Patel, TR Fuerst, HE Drummer, M Major, AW Tarr, JK Ball, M Law, BG Pierce, SKH Foung, JR Bailey
Gastroenterology | Published : 2022
Open access
Abstract
Background & Aims: Development of a prophylactic hepatitis C virus (HCV) vaccine will require accurate and reproducible measurement of neutralizing breadth of vaccine-induced antibodies. Currently available HCV panels may not adequately represent the genetic and antigenic diversity of circulating HCV strains, and the lack of standardization of these panels makes it difficult to compare neutralization results obtained in different studies. Here, we describe the selection and validation of a genetically and antigenically diverse reference panel of 15 HCV pseudoparticles (HCVpps) for neutralization assays. Methods: We chose 75 envelope (E1E2) clones to maximize representation of natural polymor..
View full abstractGrants
Awarded by Danmarks Frie Forskningsfond
Funding Acknowledgements
Support was received by National Institutes of Health, National Institute of Allergy and Infectious Diseases grants AI127469 and AI088791 to Justin R. Bailey, AI079031 and AI123861 grants to Mansun Law, grant AI123862 to Steven K.H. Foung, grant AI132213 Thomas R. Fuerst, Brian G. Pierce, and Steven K.H. Foung, grant AI144083 to Thomas R. Fuerst and Brian G. Pierce and graduate training grant T32 AI125186 to Johnathan D. Guest. Jonathan K. Ball, Alexander W. Tarr, and Richard A. Urbanowicz are supported by Medical Research Council grant number MR/R010307/1. Arvind H. Patel, Vanessa M. Cowton, and Sarah J. Cole are supported by the United Kingdom Medical Research Council grant MC_UU12014/2.